Rose Sheridan

1.5k total citations
38 papers, 1.2k citations indexed

About

Rose Sheridan is a scholar working on Molecular Biology, Pharmacology and Organic Chemistry. According to data from OpenAlex, Rose Sheridan has authored 38 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 25 papers in Molecular Biology, 15 papers in Pharmacology and 14 papers in Organic Chemistry. Recurrent topics in Rose Sheridan's work include Microbial Natural Products and Biosynthesis (15 papers), CRISPR and Genetic Engineering (7 papers) and Carbohydrate Chemistry and Synthesis (6 papers). Rose Sheridan is often cited by papers focused on Microbial Natural Products and Biosynthesis (15 papers), CRISPR and Genetic Engineering (7 papers) and Carbohydrate Chemistry and Synthesis (6 papers). Rose Sheridan collaborates with scholars based in United Kingdom, United States and Spain. Rose Sheridan's co-authors include Barrie Wilkinson, Peter F. Leadlay, Steven J. Moss, Matthew A. Gregory, Hrvoje Petković, Rachel E. Lill, Sabine Gaisser, Alison J. Weston, Christine Martin and Carlos Olano and has published in prestigious journals such as Angewandte Chemie International Edition, Blood and Cancer Research.

In The Last Decade

Rose Sheridan

35 papers receiving 1.1k citations

Peers

Countries citing papers authored by Rose Sheridan

Since Specialization

Citations

This map shows the geographic impact of Rose Sheridan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Rose Sheridan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Rose Sheridan more than expected).

Fields of papers citing papers by Rose Sheridan

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Rose Sheridan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Rose Sheridan. The network helps show where Rose Sheridan may publish in the future.

Co-authorship network of co-authors of Rose Sheridan

This figure shows the co-authorship network connecting the top 25 collaborators of Rose Sheridan. A scholar is included among the top collaborators of Rose Sheridan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Rose Sheridan. Rose Sheridan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Liver Gene Therapy 2022 ·Human Gene Therapy ·Amit C. Nathwani, Jenny McIntosh, Rose Sheridan	18
2	In Vitro Hydrodynamic Assessment of a New Transcatheter Heart Valve Concept (the TRISKELE) 2016 ·Journal of Cardiovascular Translational Research ·Benyamin Rahmani, (unknown), Rose Sheridan, Michael Mullen, John Yap, Alexander M. Seifalian, Gaetano Burriesci	32
3	A new transcatheter heart valve concept (the TRISKELE): feasibility in an acute preclinical model 2016 ·EuroIntervention ·Benyamin Rahmani, (unknown), Rose Sheridan, Michael Mullen, John Yap, Alexander M. Seifalian, Gaetano Burriesci	17
4	Phenytoin for neuroprotection in patients with acute optic neuritis: a randomised, placebo-controlled, phase 2 trial 2016 ·The Lancet Neurology ·Rhian Raftopoulos, Simon J. Hickman, Ahmed Toosy, Basil Sharrack, Shahrukh Mallik, David Paling, Daniel R. Altmann, Marios Yiannakas, (unknown), Rose Sheridan, Ptolemaios G. Sarrigiannis, Nigel Hoggard, Martin Koltzenburg, Claudia A. M. Gandini Wheeler‐Kingshott, Klaus Schmierer, Gavin Giovannoni, David H. Miller, Raju Kapoor	138
5	Recombinant strains for the enhanced production of bioengineered rapalogs 2012 ·Metabolic Engineering ·Steven G. Kendrew, Hrvoje Petković, Sabine Gaisser, (unknown), Matthew A. Gregory, Nigel J. Coates, Mohammad Nur‐e‐Alam, (unknown), (unknown), Teresa A. Foster, Leonard A. McDonald, (unknown), Frank E. Koehn, Jerauld S. Skotnicki, Guy T. Carter, Steven J. Moss, Ming‐Qiang Zhang, Christine Martin, Rose Sheridan, Barrie Wilkinson	11
6	Engineered biosynthesis of hybrid macrolide polyketides containing d-angolosamine and d-mycaminose moieties 2008 ·Organic & Biomolecular Chemistry ·Ursula Schell, Stephen Haydock, (unknown), Isabelle Carletti, Rachel E. Lill, Eliot Read, (unknown), (unknown), María‐José Fernández, (unknown), Hamish A. I. McArthur, Rose Sheridan, Peter F. Leadlay, Barrie Wilkinson, Sabine Gaisser	26
7	Brain-selective mTOR inhibitors as potential therapeutics for glioblastoma multiforme 2006 ·Cancer Research ·Rose Sheridan, Matthew A. Gregory, Hrvoje Petković, Sabine Gaisser, (unknown), Michael J. Ward, (unknown), (unknown), Iain R. Challis, Steven J. Moss, Barrie Wilkinson, Peter J. Houghton, Ming‐Qiang Zhang	1
8	Rapamycin biosynthesis: elucidation of gene product function 2006 ·Organic & Biomolecular Chemistry ·Matthew A. Gregory, Hui Hong, Rachel E. Lill, Sabine Gaisser, Hrvoje Petković, (unknown), (unknown), Isabelle Carletti, (unknown), Michael J. Ward, (unknown), Alison J. Weston, Iain R. Challis, Peter F. Leadlay, Christine Martin, Barrie Wilkinson, Rose Sheridan	40
9	Separation of anti-angiogenic and cytotoxic activities of borrelidin by modification at the C17 side chain 2006 ·Bioorganic & Medicinal Chemistry Letters ·Barrie Wilkinson, Matthew A. Gregory, Steven J. Moss, Isabelle Carletti, Rose Sheridan, (unknown), Michael J. Ward, Carlos Olano, Cármen Méndez, José A. Salas, Peter F. Leadlay, (unknown), Ming‐Qiang Zhang	37
10	Biosynthesis of the angiogenesis inhibitor borrelidin: directed biosynthesis of novel analogues 2006 ·Chemical Communications ·Steven J. Moss, Isabelle Carletti, Carlos Olano, Rose Sheridan, Michael J. Ward, (unknown), Mohammad Nur‐e‐Alam, Alfredo F. Braña, (unknown), Peter F. Leadlay, Cármen Méndez, José A. Salas, Barrie Wilkinson	37
11	Mutasynthesis of Rapamycin Analogues through the Manipulation of a Gene Governing Starter Unit Biosynthesis 2005 ·Angewandte Chemie International Edition ·Matthew A. Gregory, Hrvoje Petković, Rachel E. Lill, Steven J. Moss, Barrie Wilkinson, Sabine Gaisser, Peter F. Leadlay, Rose Sheridan	84
12	Biosynthesis of the angiogenesis inhibitor borrelidin by Streptomyces parvulus Tü4055: insights into nitrile formation^† 2004 ·Molecular Microbiology ·Carlos Olano, Steven J. Moss, Alfredo F. Braña, Rose Sheridan, (unknown), Alison J. Weston, Cármen Méndez, Peter F. Leadlay, Barrie Wilkinson, José A. Salas	67
13	Isolation and Characterization of Pre‐rapamycin, the First Macrocyclic Intermediate in the Biosynthesis of the Immunosuppressant Rapamycin by S. hygroscopicus 2004 ·Angewandte Chemie International Edition ·Matthew A. Gregory, Sabine Gaisser, Rachel E. Lill, Hui Hong, Rose Sheridan, Barrie Wilkinson, Hrvoje Petković, Alison J. Weston, Isabelle Carletti, (unknown), James Staunton, Peter F. Leadlay	36
14	Biosynthesis of the Angiogenesis Inhibitor Borrelidin by Streptomyces parvulus Tü4055 2004 ·Chemistry & Biology ·Carlos Olano, Barrie Wilkinson, César Sánchez, Steven J. Moss, Rose Sheridan, (unknown), Alison J. Weston, Alfredo F. Braña, Christine Martin, Markiyan Oliynyk, Cármen Méndez, Peter F. Leadlay, José A. Salas	130
15	Heterologous expression in Saccharopolyspora erythraea of a pentaketide synthase derived from the spinosyn polyketide synthaseElectronic supplementary information (ESI) available: Further details of the construction of pCJR308, the fermentation of BIOT-0966 and the isolation of pentaketide lactone, 3, and figures showing the13C NMR and 1H COSY spectra of 3. See http://www.rsc.org/suppdata/ob/b3/b310740j/ 2003 ·Organic & Biomolecular Chemistry ·Christine Martin, (unknown), Rose Sheridan, Steven G. Kendrew, Barrie Wilkinson, James Staunton, Peter F. Leadlay	32
16	A Novel Erythromycin, 6-Desmethyl Erythromycin D, Made by Substituting an Acyltransferase Domain of the Erythromycin Polyketide Synthase 2003 ·The Journal of Antibiotics ·Hrvoje Petković, Rachel E. Lill, Rose Sheridan, Barrie Wilkinson, Ellen L. McCormick, Hamish A. I. McArthur, James Staunton, Peter F. Leadlay, Steven G. Kendrew	32
17	Direct production of ivermectin-like drugs after domain exchange in the avermectin polyketide synthase of Streptomyces avermitilis ATCC31272 2003 ·Organic & Biomolecular Chemistry ·Sabine Gaisser, Laurenz Kellenberger, (unknown), Alison J. Weston, Rachel E. Lill, Gabriele Wirtz, Steven G. Kendrew, (unknown), Rose Sheridan, Barrie Wilkinson, (unknown), K J Stutzman-Engwall, Hamish A. I. McArthur, James Staunton, Peter F. Leadlay	35
18	Engineered biosynthesis of novel spinosyns bearing altered deoxyhexose substituentsElectronic supplementary information (ESI) available: 1H and 13C NMR data for compounds 5–8. See http://www.rsc.org/suppdata/cc/b2/b200536k/ 2002 ·Chemical Communications ·Sabine Gaisser, Christine Martin, Barrie Wilkinson, Rose Sheridan, Rachel E. Lill, Alison J. Weston, (unknown), Clive Waldron, Gary D. Crouse, Peter F. Leadlay, James Staunton	26
19	SB-253514 and Analogues. Novel Inhibitors of Lipoprotein-Associated Phospholipase A2 Produced by Pseudomonas fluorescens DSM 11579. I. Fermentation of Producing Strain, Isolation and Biological Activity. 2000 ·The Journal of Antibiotics ·(unknown), (unknown), Helen Boyd, Murray Brown, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), José-María Sánchez-Puelles, Rose Sheridan, (unknown), S. R. C. Warr	48
20	Rational engineering of the TOLmeta-cleavage pathway 1998 ·Biotechnology and Bioengineering ·Rose Sheridan, (unknown), (unknown), John M. Ward, Peter Dunnill	7

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact